Immunoglobulin E and House Dust Mite Allergen Epitopes (IgE/HDM Epitopes)

Immunoglobulin E (IgE) is a specialized antibody class that plays a central role in type I hypersensitivity reactions, particularly in response to house dust mite (HDM) allergens from Dermatophagoides pteronyssinus and Dermatophagoides farinae. These mites produce potent allergenic proteins, such as Der p 1, Der p 2, Der f 1, and Der f 2, which contain specific epitopes recognized by the immune system of sensitized individuals [Source: WHO/IUIS Allergen Nomenclature]. When these HDM epitopes cross-link IgE molecules bound to high-affinity receptors (FcεRI) on the surface of mast cells and basophils, they trigger the immediate release of inflammatory mediators like histamine, leukotrienes, and cytokines, leading to the clinical symptoms of allergic asthma and rhinitis [Source: Nature Reviews Immunology]. Therapeutic interventions target this pathway either by neutralizing circulating IgE using monoclonal antibodies like Omalizumab or by modifying the immune response through allergen immunotherapy (AIT). AIT utilizes controlled exposure to HDM epitopes to desensitize the patient, promoting the development of regulatory T cells and the production of IgG4 antibodies that block the IgE-allergen interaction [Source: PubMed, PMID: 28433318].

Other names

IgEHouse Dust Mite AllergensDer p 1Der p 2Der f 1Der f 2HDM-specific IgEDermatophagoides pteronyssinus allergensDermatophagoides farinae allergens

Anti-IgE monoclonal antibodies (e.g., Omalizumab) bind to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils [Source: FDA Label, Xolair]. Allergen immunotherapy (AIT) involves the administration of specific HDM epitopes to induce immunological tolerance, characterized by the induction of regulatory T cells (Tregs), a shift from Th2 to Th1 immune responses, and the production of 'blocking' IgG4 antibodies that compete with IgE for allergen binding [Source: JACI, 2017].